Contact Us
Click here to contact Felicity Thomas,editor.
June 05, 2013
NICE gives wet AMD therapy green light The National Institute for Health and Care Excellence (NICE) has announced that Eylea (aflibercept, Bayer HealthCare, Leverkusen, Germany) should be recommended for the treatment of patients with wet age related macular degeneration (wAMD). More...
Positive results from BIOFLOW-II clinical trial Primary endpoint results, demonstrating the non-inferiority of the BIOTRONIK Orsiro hybrid drug-eluting stent compared to Abbott's XIENCE PRIME, from the BIOFLOW-II clinical study have been revealed at the EuroPCR congress in Paris. More...
VMT treatment launched in Denmark and Sweden JETREA (ThromboGenics, Leuven, Belgium) has launched in Denmark and Sweden with roll out of the drug to follow shortly in Finland and Norway. These launches will be performed by ThromboGenics partner, Alcon. More...
Encouraging results for device to treat wAMD Long-term positive outcomes of a minimally invasive retrobulbar episcleral brachytherapy device (SalutarisMD, Salutaris Medical Devices, London, UK) show promise for treating wet age-related macular degeneration (wAMD), according to data presented at the RCO congress. More...
